DJIA 16,204.97 0.00 0.00%
NASDAQ 4,363.14 0.00 0.00%
S&P 500 1,880.05 0.00 0.00%
market minute promo

CEL-SCI Corp (NYSEMKT: CVM)

0.46 0.00 (0.00%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

CVM $0.46 0.00%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.46
Previous Close $0.46
Daily Range $0.46 - $0.50
52-Week Range $0.36 - $1.23
Market Cap $59.9M
P/E Ratio -1.14
Dividend (Yield) $0.00 (0.0%)
Volume 499,404
Average Daily Volume 688,989
Current FY EPS -$0.29

Sector

Healthcare

Industry

Drug Makers

CEL-SCI Corp (CVM) Description

The Company engages in the research and development of drugs and vaccines. Its most advanced product, Multikine, manufactured using the Company's proprietary cell culture technologies, is being developed for the treatment of cancer. Website: http://www.cel-sci.com/

News & Commentary Rss Feed

One Biotech Stock to Avoid

Our investing community's latest pick to avoid: Vical.

CEL-SCI Corp (CVM) Shows Strength: Stock Moves Up 8.3%

CEL-SCI's Rheumatoid Arthritis Vaccine Selected for Commercialization & Program Niche Analysis Plan

CEL-SCI's Rheumatoid Arthritis Vaccine Selected for Commercialization & Program Niche Analysis Plan by U.S. National Institutes of Health

Cel-Sci: Phase III Enrollment Numbers Announced, Arbitration Pushed Back, Diutive Financing

Interesting Developments For Cel-Sci's Upcoming Court-Date With Its Former CRO, InVentiv Clinical

Risks And Rewards For Cel-Sci: Phase III And Phase I Progress, And Arbitration

CEL-SCI Reports September Patient Enrollment for Its Phase 3 Head and Neck Cancer Trial

CEL-SCI Expands Its Phase I Study for Treatment of Anal Warts in HIV/HPV Co-Infected Patients with A

CEL-SCI Expands Its Phase I Study for Treatment of Anal Warts in HIV/HPV Co-Infected Patients with Addition of 2nd Site at University of California San Francisco

CEL-SCI Reports June Patient Enrollment in Its Phase 3 Head and Neck Cancer Trial

CEL-SCI Reports Clearance to Start Patient Enrollment in Phase 3 Cancer Immunotherapy Trial in Thail

CEL-SCI Reports Clearance to Start Patient Enrollment in Phase 3 Cancer Immunotherapy Trial in Thailand

Next Week In Biotech: Salix/Valeant PDUFA, ASCO, Brain Tumor Summit

See More CVM News...

CVM's Top Competitors

CVM $0.46 (0.00%)
Current stock: CVM
AMGN $145.04 (0.00%)
Current stock: AMGN
GILD $85.14 (0.00%)
Current stock: GILD
BIIB $263.86 (0.00%)
Current stock: BIIB